rNAPc2 Publications
Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP.
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
The Lancet 2003 December 13;362(9400):1953-1958.
Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van Der MJ, Piovella F, Raskob G, Gent M.
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.
Circulation 2001 July 3;104(1):74-78.
Moons AH, Peters RJ, Bijsterveld NR, Piek JJ, Prins MH, Vlasuk GP, Rote WE, Buller HR.
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.
Journal of the American College of Cardiology 2003 June 18;41(12):2147-2153.
Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS.
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Cancer Research 2003 June 1;63(11):2997-3000.
Scientific Presentations
Zhao J, Aguilar G, Abo A and the Department of Research, Nuvelo
rNAPc2 inhibits colorectal cancer in mouse models through tissue factor
American Association for Cancer Research (AACR) 2008 Annual Meeting
April 16, 2008
Binnerts M, Kim K, Bright J, Leung J, Patel S, Tran K, Zhou M, Liu Y, Lomas W, Dixon M, Hazell S, Wagle M, Williams J, Zhan X, Levy M, Funk W, and Abo, A.
R-Spodin 1 regulates Wnt Signaling by Inhibiting Internalization of LRP6
AACR-NCI-EORTC Conference
October 2007 (Poster)
Zhao J, Aguilar G, Deitcher S, Funk W, Abo A and the Departments of Research and Medical Science, Nuvelo
rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Suppresses Lung Metastasis and Synergizes with 5-FU or Bevacizumab in Mouse Models of Colorectal Cancer
American Society of Hematology 48th Annual Meeting and Exposition
Supporting Materials: rNAPc2 Phase 2 Efficacy Data Presentation
December 9, 2006 (Poster)
Wiviott D, Stone PH, Bouchard A, Alshaher M, Goulder MA, Deitcher SR, Giugliano RP on behalf of the ANTHEM-TIMI 32 Investigators
F1.2 Correlates with Ischemia by Holter Monitoring and is Suppressed by rNAPc2: an ANTHEM-TIMI 32 Biomarker Analysis
American Heart Association Scientific Sessions 2006
Supporting Materials:
rNAPc2 Phase 2 Efficacy Data Presentation
November 13, 2006 (Poster)
Giugliano RP, Wiviott SD, Simon DI, Schweiger MJ, Leesar MA, Stone PH, Bach R, Skene A, Deitcher SR, Braunwald E on behalf of the ANTHEM-TIMI 32 Investigators
Novel Tissue Factor/Factor VIIa Inhibitor Reduces Ischemia in Patients with nSTE-ACS: Results of the Dose-Ranging and Heparin De-Escalation Phases of the ANTHEM-TIMI 32 Trial
Transcatheter Cardiovascular Therapeutics 2006 Conference
Supporting Materials:
rNAPc2 Phase 2 Efficacy Data Presentation
October 23, 2006, 5:47 PM ET (Slides)
Narula T, Southard MC, Gibson CM, Bouchard A, Singh VN, Goulder M, Deitcher SR, Giugliano RP on behalf of the ANTHEM-TIMI 32 Investigators
Outcomes in Patients with nSTE-ACS Undergoing PCI on a Novel Tissue Factor/Factor VIIa Inhibitor (rNAPc2) with Full, Half-Dose or No Heparin in the ANTHEM-TIMI 32 Trial
Transcatheter Cardiovascular Therapeutics 2006 Conference
Supporting Materials:
rNAPc2 Phase 2 Efficacy Data Presentation
October 22-27, 2006, (Electronic Poster)
Fluture A, Giugliano GR, Schweiger MJ, Southard MC, Gibson CM, Buros J, Goulder MA, Deitcher S, Giugliano RP on behalf on behalf of the ANTHEM-TIMI 32 Investigators
Angiographic Outcomes in Patients with Non-STE ACS Undergoing PCI Using Adjunctive Recombinant Nematode Anticoagulant Protein c2 Versus Placebo: An ANTHEM-TIMI 32 Angiographic Core Lab Analysis
Transcatheter Cardiovascular Therapeutics 2006 Conference
Supporting Materials: rNAPc2 Phase 2 Efficacy Data Presentation
October 22-27, 2006, (Electronic Poster)
Giugliano RP, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Goulder M, Deitcher SR, Braunwald E on behalf of the ANTHEM-TIMI 32 Investigators
Tissue Factor/fVIIa Inhibition with Higher-dose rNAPc2 Reduces Ischemia in Patients with NSTE-ACS Managed with an Early Invasive Strategy in ANTHEM-TIMI 32
World Congress of Cardiology 2006
Supporting Materials: rNAPc2 Phase 2 Efficacy Data Presentation
September 5, 2006, 1:30 PM PT (Webcast) (Slides)
Giugliano RP, Wiviott SD, Morrow DA, Simon DI; Schweiger MJ; Chandra M; Deitcher SR; Skene A; Braunwald E
Addition of a Tissue-Factor/Factor VIIa Inhibitor to Standard Treatments in NSTE-ACS Managed with an Early Invasive Strategy: Results of the Phase 2 ANTHEM-TIMI 32 Double-Blind Randomized Clinical Trial
American Heart Association's Scientific Sessions 2005
Supporting Materials: Nuvelo Update on Cardiovascular Programs Surrounding rNAPc2 Data Presentation at AHA Scientific Sessions 2005
November 14, 2005 (Slides)
The attached publications and presentations reflect the actual data and other content prepared by the author(s) and presenter(s) as of the date indicated for each publication or presentation. Nuvelo disclaims any obligation to update the data reflected in these publications and presentations.